Hints and tips:
Refine results
Bayer-Temasek, Shire-Allergan, Aviva, FCA-Barclays, Buffett-USG, IBM, Netflix and Facebook
Choking off copycat drugs is a bad strategy
FT 1000 Asia-Pacific list shows sector is another friendly rivalry to span the Tasman Sea
Doubts hang over acquisitions struck when the industry was in the grip of an M&A frenzy
Clinical setbacks in cancer research are likely to be punished
Swiss group focuses on pharma as $13bn deal hands UK partner control of consumer unit
Move to shed consumer health unit by Swiss group’s new CEO aims at focusing business
Failure to sell its consumer healthcare unit has left pharma group looking for a cure
Pharma group’s decision not to bid for consumer healthcare unit puts sale in doubt
A deal could give significant lift to earnings after three years
Reckitt’s decision to abandon potential $20bn deal cheered by some but rued by others
Drugmaker tops Reckitt Benckiser bid for consumer health business
Flu victim should have paid much less for her medication, data show
Rival Reckitt Benckiser falls back in the bidding for Advil maker
Staff cuts come as losses continue across most of firm’s portfolio
Takeover of pharmacy benefits manager to provide clout when buying drugs and services
Biotech company Revance hopes its rival treatments will put the squeeze on Allergan
Biotech companies plan to use the technique to treat blood diseases and blindness
Small ‘organoids’ grown in the lab could be used to treat chronic conditions
Authorities are investigating whether companies aggravated a shortage of the vital medical product to boost profits
Clear all selected filters
